Immunetune to Present Data on Neoantigen Cancer Vaccine Platform at SITC 2021
LEIDEN, the Netherlands, October 1, 2021 — Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the upcoming presentation of data on its neoantigen DNA cancer vaccine platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021. The submitted abstract was selected for a poster presentation during the SITC conference, taking place virtually and physically in Washington, D.C., from November 10 – 14, 2021.
The selected abstract is titled “Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity”. Abstracts can be accessed on the SITC website once the conference begins on November 9; posters will be presented on November 12 and 13.
“It is an exciting opportunity to present our latest preclinical data at a leading international scientific and medical conference. Building upon our publication in the journal OncoImmunology in 2019, these data now include the combination of our synthetic, linear DNA cancer vaccine platform with a novel adjuvant that targets pyroptosis to elicit a potent T cell response against tumor-specific neoantigens,” stated Jeroen van Bergen, CSO of Immunetune, and presenter of the poster at SITC.
Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free production of personalized cancer vaccines encoding multiple (neo-)antigens in synthetic, linear DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting antigens conserved across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.
For more information, please contact:
Chief Executive Officer
Telephone: +31 71 3322 388